

EUROPE'S LEADING COMPREHENSIVE CANCER CENTRE

**GUSTAVE /
ROUSSY** —
CANCER CAMPUS
GRAND PARIS



A UNIQUE MODEL FOR THE PAST CENTURY



- **Europe's leading comprehensive cancer centre**
- A **high quality** care of every type of cancer, at any age and in the treatment of rare and complex tumours
- **Internationally** renowned professionals for a huge dynamic of **progress and innovation**
- **Cutting-edge equipments** to treat patients with the most advanced methods
- **Values** of creativity, dynamism, communication and compassion

INTERNATIONAL RECOGNITION

- #5 world's leading oncology hospital according to Newsweek



- 12 researchers of Gustave Roussy listed in the 2020's Highly Cited Researchers List published by Web of Science Group (Clarivate Analytics). The list names the most influential researchers in the world.

46,120

patients seen in in-clinic
of whom **10,400** (including
400 in pediatrics) had their
first appointment

446 M€

overall budget

471

beds

&

133

places in
day hospital

26

university
diplomas

2,500

students and
practicians trained

8,700

students trained
online

14,000

registered students on the digital
learning platform of the
École des sciences du cancer

3,200


employees

22%

of the patients treated were
involved in a clinical research

89

patent
families



AN INTERNATIONAL DEVELOPMENT STRATEGY

- Since thirty years, Gustave Roussy welcomes **foreign patients**: about 1,400 foreign patients admitted every year, representing 5 to 7% of the number of patients (*outside the Covid-19 pandemic period*).
- Single or multi-year **hospital projects abroad** with partner countries: Kazakhstan, Kuwait, United Arab Emirates, Russia, Morocco, Algeria... in order to:
 - create new infrastructures,
 - improve access to care for all patients and treat them in their country,
 - train staffs.
- Cancer Core Europe, a european consortium initiated by Gustave Roussy, brings together the seven largest Comprehensive Cancer Centres in Europe



60,000

new diagnoses

300,000

cancer treatments provided

1,000,000

outpatient visits


1,500

clinical trials

A NEW INSTITUTIONAL STRATEGIC PLAN

GUSTAVE ROUSSY 2030

CANCER CAMPUS
GRAND PARIS



A plan perfectly aligned with the ten-year strategy of the Inca presented by the French President of the Republic on February 4, 2021:

Strategic axes of the State Cancer Plan

Axe 1 - Improving prevention

Axe 2 - Limiting the after-effects and improving quality of life

Axe 3 - Fight against cancers with a poor prognosis

Axe 4 - Ensure that all progress benefits everyone

GIVING HOPE TO EACH PATIENT

The patient at the heart of our strategy:

Quality and safety of care, a policy of partner patients, whether French or international.

From before to after cancer:

Personalized prevention to intercept cancers, rapid diagnosis, better after-cancer.

Broader expertise:

Recourse treatment at earlier stages, traditional recourse redefined, development model rethought.

SHEDDING LIGHT ON ONCOLOGY

Socially useful integrative research:

10 major medical-scientific programs, innovative platforms, a "major trials" strategy, paramedical research and a strengthened development policy.

Teaching at the heart of our mission:

Gustave Roussy, anchored in the Paris-Saclay University dynamic, for a structured education, opening to new professions and certifications.

Gustave Roussy, a public health player and driver of change:

A renewed communication around an advocacy and networking strategy.

STRENGTHEN THE HOUSE GUSTAVE ROUSSY

A collective in which working is an opportunity:

More agile management, an attractiveness policy, QWL initiatives;


A redesigned organization: :

Sustainable management based on the group's values, more adapted statutes, an integrated care production system, a green ambition.

Consolidated resources to support our ambitions:

A demanding philanthropy strategy, a new real estate master plan, a secure business model.

AN AMBITIOUS POLICY OF INTERNATIONAL DEVELOPMENT



CANCER CAMPUS, TOWARD A MAJOR HUB IN GRAND PARIS

- International biocluster dedicated to innovation in oncology
- A redesigned academic research centre
- A renovated and denser hospital complex



Objective:

gather the cutting-edge research and training, facilitated by a simplified access thanks to underground building (lines 14 and 15) in 2024

CONDUCTING
DARING RESEARCH



RESEARCH, AT THE HEART OF INNOVATION

- The activities of the Institute's research units are concentrated on:
 - **personalised medicine**, to propose targeted treatments,
 - **immunotherapy**, to stimulate and strengthen the patient's own defences against malignant cells,
 - **DNA repair** techniques to facilitate understanding of molecular mechanisms,
 - **artificial intelligence**, to improve diagnosis and cancer prediction.

- To generate innovative treatments, Gustave Roussy **gathers in the same place**:
 - **fundamental** research,
 - **clinical** research,
 - **translational** research.



36
research teams and
10 research units

1,000
Research staff

374
patients included
in phases I and I/II trials

220
clinical trials in immunotherapy
since 2013, of which **56** in 2019

524
clinical trials

241
trials sponsored by Gustave Roussy

3,156
Gustave Roussy's patients included in
clinical trials

171
Publications
with IF between > 30

380
international publications
with an impact factor >10
(excluding congress)

103 M€
dedicated to research on
the Gustave Roussy site

OFFERING INNOVATIVE CARE



A CUTTING-EDGE CARE, FROM DIAGNOSIS TO TREATMENT

- Proposing **the most advanced and innovative treatments**
- **Developing new therapies** thanks to advanced technical support services
- **Speeding up the delivery of innovative treatments to patients** with its Drugs Development Department (Ditep)

124 690

stays (excluding radiotherapy)
including **19 460** stays in full
hospitalization

8,820

hospital stays in full admission
including **890** in pediatrics

12 470

ambulatory stays
(excluding radiotherapy)

277,000

medical consultations

Expert in

rare and complex

cancers

CARE

3,800

patients treated by radiotherapy

13,270

sessions of tomotherapy
and **540** patients treated

6,140

patients treated with
chemotherapy

2,610

patients treated by
interventional radiology

4,250

patients treated by
surgery

PASSING ON
EXPERTS' KNOWLEDGE



3,300

students and praticians trained
and **8,700** trained online

240

practitioner teachers

academic or private

courses

215

doctoral students
at the Ecole doctorale de
cancérologie

26

university diplomas

40

seminars
and master classes

TEACHING

14,000

registered students on the digital
learning plateforme of the
École des sciences du cancer

30,000

hours devoted to training,
3,000 of those being at
university level

a course on

anti-tumour chemotherapy

for oncologists

200,000

downloads of articles
and e-books

- The **École des sciences du cancer** and the **École Doctorale de Cancérologie**, two unique institutions devoted to oncology in France
- **A close connection** with Paris-Saclay high level engineering schools:
 - A new double degree at the IFSBM to train the best bioengineer, thanks to the Paris-Saclay partnership
 - Several artificial intelligence projects with CentraleSupélec

AN OUTSTANDING SCIENTIFIC ENVIRONMENT WITH PARIS-SACLAY



MOBILISING **GIVING**
AGAINST CANCER



PUBLIC GENEROSITY, A CONTRIBUTION TO PROGRESS

- Private establishment of collective benefit, Gustave Roussy can **receive donations and bequests**
- The **Gustave Roussy Research Foundation** facilitates research work at the Institute
- Donations are an essential resource for financing:
 - innovation in research,
 - improvement of the patient's quality of life,
 - acquisition of latest generation equipment,
 - renovation of the departments,
 - creation of research teams.

41 M€

collected in 2020
by Gustave Roussy
and its Foundation

CURING CANCER in the 21st century

Curing cancer in the 21st century:

- support innovation in **promising therapies**, notably with immunotherapy and personalised medicine,
- ensure excellence thanks to a **cutting-edge technology**,
- **take care and assist** patients during and after their treatments.

CURING CHILDHOOD CANCER in the 21st century

Curing childhood cancer in the 21st century:

- **develop efficient immunotherapies** for children,
- **identify genetic predispositions** which cause cancer in young patients,
- **improve the cure quality** of children and adolescents to understand, detect and **prevent late complications** in adulthood,
- **accelerate research on DIPG** (diffuse intrinsic pontine glioma).

GUSTAVE /
ROUSSY -
CANCER CAMPUS
GRAND PARIS

